Literaturliste

• Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr 2009; 3(3):190–204. DOI: 10.1016/j.jcct.2009.03.004. http://www.ncbi.nlm.nih.gov/pubmed/19409872.
• Abdallah MS, Wang K, Magnuson EA, et al. Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. J Am Coll Cardiol 2017; 69(16):2039–50. DOI: 10.1016/j.jacc.2017.02.031. http://www.ncbi.nlm.nih.gov/pubmed/28427580.
• Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses. BMJ 2013; 346:f1378. http://www.ncbi.nlm.nih.gov/pubmed/23558164.
• Achenbach S, Barkhausen J, Beer M, et al. Konsensusempfehlungen der DRG/DGK/DGPK zum Einsatz der Herzbildgebung mit Computertomografie und Magnetresonanztomografie. Rofo 2012; 184(4):345–68. http://www.ncbi.nlm.nih.gov/pubmed/22426867.
• Agarwal N, Jain A, Mahmoud AN, et al. Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. Am J Med 2017; 130(11):1280–9. DOI: 10.1016/j.amjmed.2017.03.057. http://www.ncbi.nlm.nih.gov/pubmed/28460853.
• Ahn J-M, Roh J-H, Kim Y-H, et al. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. J Am Coll Cardiol 2015; 65(20):2198–206. DOI: 10.1016/j.jacc.2015.03.033. http://www.ncbi.nlm.nih.gov/pubmed/25787197.
• Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-S504. http://www.ncbi.nlm.nih.gov/pubmed/10993420.
• Alam M, Huang HD, Shahzad SA, et al. Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era—an aggregate data meta-analysis of 11,148 patients. Circ J 2013; 77(2):372–82. http://www.ncbi.nlm.nih.gov/pubmed/23123552.
• Albus C, Ladwig KH, Herrmann-Lingen C. Psychokardiologie: Praxisrelevante Erkenntnisse und Handlungsempfehlungen. Dtsch Med Wochenschr 2014; 139(12):596–601. DOI: 10.1055/s-0033-1360102. http://www.ncbi.nlm.nih.gov/pubmed/24619718.
• Al-Lamee R, Thompson D, Dehbi H-M, et al. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet 2018; 391(10115):31–40. DOI: 10.1016/S0140-6736(17)32714-9. http://www.ncbi.nlm.nih.gov/pubmed/29103656.
• Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS. One. 2014; 8(6):e65130. DOI: 10.1371/journal.pone.0065130. http://www.ncbi.nlm.nih.gov/pubmed/23755180.
• American College of Cardiology Foundation, American College of Radiology, Society of Cardiovascular Computed Tomography (SCCT), et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006; 48(7):1475–97. DOI: 10.1016/j.jacc.2006.07.003. http://www.ncbi.nlm.nih.gov/pubmed/17010819.
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130(25):e344-e426. DOI: 10.1161/CIR.0000000000000134. http://www.ncbi.nlm.nih.gov/pubmed/25249585.
• Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016(1):CD001800. DOI: 10.1002/14651858.CD001800.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26730878.
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324(7329):71–86. http://www.ncbi.nlm.nih.gov/pubmed/11786451.
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. 2016 [cited: 2018-01-17]. DOI: 10.1007/978-3-662-47086-2. http://www.awmf.org/uploads/tx_szleitlinien/076-001l_S3-Leitlinie_Alkohol_2016-02.pdf.
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsum: Registernummer 076-006, Version 2015-02. 2014 [cited: 2021-06-23]. http://www.awmf.org/leitlinien/detail/ll/076-006.html.
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012.
• Arrieta A, Hong JC, Khera R, et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol 2017; 2(12):1369–74. DOI: 10.1001/jamacardio.2017.3655. http://www.ncbi.nlm.nih.gov/pubmed/29049467.
• Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: A scientific statement from the American Heart Association. Circulation 2010; 122(4):406–41. DOI: 10.1161/CIR.0b013e3181e8edf1. http://www.ncbi.nlm.nih.gov/pubmed/20625115.
• Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8. 2008 [cited: 2019-09-05]. http://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi-fassung-2005-2006-domaene-8-2008.pdf.
• Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005; 99(8):468–519.
• Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: Where does the evidence stand in 2010? Am J Clin Nutr 2011; 93(4):684–8. DOI: 10.3945/ajcn.110.004622. http://www.ncbi.nlm.nih.gov/pubmed/21270379.
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.
• Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007; 334(7594):617. http://www.ncbi.nlm.nih.gov/pubmed/17337458.
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678):1849–60. http://www.ncbi.nlm.nih.gov/pubmed/19482214.
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493):1267–78. http://www.ncbi.nlm.nih.gov/pubmed/16214597.
• Ballmoos MW von, Haring B, Juillerat P, et al. Meta-analysis: Diagnostic performance of low-radiation-dose coronary computed tomography angiography. Ann Intern Med 2011; 154(6):413–20. DOI: 10.1059/0003-4819-154-6-201103150-00007. http://www.ncbi.nlm.nih.gov/pubmed/21403076.
• Bandelow B, Wiltink J, Alpers GW, et al. S3-Leitlinie Behandlung von Angststörungen. 2014 [cited: 2019-10-02]. https://www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_Angstst%C3%B6rungen_2014-05-abgelaufen.pdf.
• Banerjee A, Newman DR, van den Bruel A, et al. Diagnostic accuracy of exercise stress testing for coronary artery disease: A systematic review and meta-analysis of prospective studies. Int J Clin Pract 2012; 66(5):477–92. DOI: 10.1111/j.1742-1241.2012.02900.x. http://www.ncbi.nlm.nih.gov/pubmed/22512607.
• Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: A meta-analysis of randomized trials. Am J Med 2014; 127(10):939–53. DOI: 10.1016/j.amjmed.2014.05.032. http://www.ncbi.nlm.nih.gov/pubmed/24927909.
• Barlow J, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: A review. Patient Educ Couns. 2002; 48(2):177–87. http://www.ncbi.nlm.nih.gov/pubmed/12401421.
• Barth J, Schneider S, Känel R von. Lack of social support in the etiology and the prognosis of coronary heart disease: A systematic review and meta-analysis. Psychosom Med 2010; 72(3):229–38. DOI: 10.1097/PSY.0b013e3181d01611. http://www.ncbi.nlm.nih.gov/pubmed/20223926.
• Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22(1):1–23. DOI: 10.1016/j.echo.2008.11.029. http://www.ncbi.nlm.nih.gov/pubmed/19130998.
• Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22(2):229–45. DOI: 10.1007/s12350-015-0096-5. http://www.ncbi.nlm.nih.gov/pubmed/25733105.
• Bein T, Bischoff M, Brückner U, et al. Lagerungstherapie und Frühmobilisation zur Prophylaxe oder Therapie von pulmonalen Funktionsstörungen. S2e-Leitlinie. 2015 [cited: 2018-04-20]. http://www.awmf.org/uploads/tx_szleitlinien/001-015l_S2e_Lagerungstherapie_Fr%C3%BChmobilisation_pulmonale_Funktionsst%C3%B6rungen_2015-05.pdf.
• Berlin-Chemie AG, Gelbe Liste Online. Ranexa® 375 mg Retardtabletten. Fachinformation. 2016 [cited: 2018-06-08]. http://www.gelbe-liste.de/produkte/Ranexa-375-mg-Retardtabletten_511772/fachinformation.
• Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102(6):624–9. http://www.ncbi.nlm.nih.gov/pubmed/10931801.
• Beygui F, Cayla G, Roule V, et al. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. J Am Coll Cardiol 2016; 67(16):1917–27. DOI: 10.1016/j.jacc.2016.02.033. http://www.ncbi.nlm.nih.gov/pubmed/27102506.
• Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39(1):9–14. http://www.ncbi.nlm.nih.gov/pubmed/11755280.
• Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC. Cardiovasc Interv. 2013; 6(1):20–6. DOI: 10.1016/j.jcin.2012.09.008. http://www.ncbi.nlm.nih.gov/pubmed/23347858.
• Blazek S, Rossbach C, Borger MA, et al. Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial. JACC Cardiovasc Interv 2015; 8(1 Pt A):30–8. DOI: 10.1016/j.jcin.2014.08.006. http://www.ncbi.nlm.nih.gov/pubmed/25499302.
• Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356(15):1503–16. http://www.ncbi.nlm.nih.gov/pubmed/17387127.
• Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: Six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008; 118(4):381–8. http://www.ncbi.nlm.nih.gov/pubmed/18606919.
• Bösner S, Becker A, Abu HM, et al. Accuracy of symptoms and signs for coronary heart disease assessed in primary care. Br J Gen Pract 2010; 60(575):e246-e257. http://www.ncbi.nlm.nih.gov/pubmed/20529488.
• Bosner S, Becker A, Haasenritter J, et al. Chest pain in primary care: Epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009; 15(3):141–6. DOI: 10.3109/13814780903329528. http://www.ncbi.nlm.nih.gov/pubmed/19883149.
• Bosner S, Haasenritter J, Becker A, et al. Ruling out coronary artery disease in primary care: Development and validation of a simple prediction rule. CMAJ 2010; 182(12):1295–300. http://www.ncbi.nlm.nih.gov/pubmed/20603345.
• Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011; 57(5):538–45. http://www.ncbi.nlm.nih.gov/pubmed/21272743.
• Brandão SM, Hueb W, Ju YT, et al. Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. Medicine (Baltimore) 2017; 96(50):e9113. DOI: 10.1097/MD.0000000000009113. http://www.ncbi.nlm.nih.gov/pubmed/29390308.
• Bruyne B de, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 2014; 371(13):1208–17. DOI: 10.1056/NEJMoa1408758. http://www.ncbi.nlm.nih.gov/pubmed/25176289.
• Bucci C, Jackevicius C, McFarlane K, et al. Pharmacist's contribution in a heart function clinic: Patient perception and medication appropriateness. Can J Cardiol 2003; 19(4):391–6. http://www.ncbi.nlm.nih.gov/pubmed/12704485.
• Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für diagnostische und interventionelle Röntgenuntersuchungen. 2010 [cited: 2017-06-26]. http://www.bfs.de/SharedDocs/Downloads/BfS/DE/fachinfo/ion/drw-roentgen.pdf?__blob=publicationFile&v=1.
• Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Untersuchungen. 2012 [cited: 2017-06-26]. http://www.laekb.de/files/1456FC3088F/Referenzwerte_Nuklearmedizin.pdf.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Langfassung, 2. Auflage. Version 3. 2017 [cited: 2018-04-23]. DOI: 10.6101/AZQ/000405. http://doi.org/10.6101/AZQ/000405.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 4. Auflage. Version 1. 2016 [cited: 2017-06-26]. DOI: 10.6101/AZQ/000267. http://doi.org/10.6101/AZQ/000267.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Leitlinienreport, 5. Auflage. Version 1. 2019 [cited: 2019-04-11]. DOI: 10.6101/AZQ/000441. http://doi.org/10.6101/AZQ/000441.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Leitlinienreport, Version 6.0: [in Erstellung]. 2022 [cited: 2022-07-05]. DOI: 10.6101/AZQ/000490. http://doi.org/10.6101/AZQ/000490.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes - Langfassung, 1. Auflage. Version 4. 2014 [cited: 2017-01-12]. DOI: 10.6101/AZQ/000213. http://doi.org/10.6101/AZQ/000213.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2019-09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-5.
• Bundesministerium der Justiz und für Verbraucherschutz (BMJV). § 630e Aufklärungspflichten. In: Bundesministerium der Justiz und für Verbraucherschutz (BMJV), editor. Bürgerliches Gesetzbuch (BGB); 2017.
• Buszman PE, Buszman PP, Banasiewicz-Szkróbka I, et al. Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial. JACC Cardiovasc Interv 2016; 9(4):318–27. DOI: 10.1016/j.jcin.2015.10.044. http://www.ncbi.nlm.nih.gov/pubmed/26892080.
• Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008; 51(5):538–45. http://www.ncbi.nlm.nih.gov/pubmed/18237682.
• Campbell NC, Thain J, Deans HG, et al. Secondary prevention clinics for coronary heart disease: Randomised trial of effect on health. Br Med J 1998; 316(7142):1434–7. http://www.ncbi.nlm.nih.gov/pubmed/9572758.
• Canadian Cardiovascular Society (CCS). Grading of angina. 1976 [cited: 2014-09-09]. http://ccs.ca/images/Guidelines/PositionStatements/Grading_of_Angina.pdf.
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377(16):1513–24. DOI: 10.1056/NEJMoa1708454. http://www.ncbi.nlm.nih.gov/pubmed/28844193.
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25):2387–97. DOI: 10.1056/NEJMoa1410489. http://www.ncbi.nlm.nih.gov/pubmed/26039521.
• Cao C, Manganas C, Bannon P, et al. Drug-eluting stents versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of early outcomes from randomized and nonrandomized studies. J Thorac Cardiovasc Surg 2013; 145(3):738–47. DOI: 10.1016/j.jtcvs.2012.02.004. http://www.ncbi.nlm.nih.gov/pubmed/22405674.
• Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of randomized clinical data. J Am Coll Cardiol 2011; 58(14):1426–32. DOI: 10.1016/j.jacc.2011.07.005. http://www.ncbi.nlm.nih.gov/pubmed/21939824.
• Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321(6):406–12. http://www.ncbi.nlm.nih.gov/pubmed/2473403.
• Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): Mode-of-death results. JACC Heart Fail 2013; 1(5):400–8. DOI: 10.1016/j.jchf.2013.04.012. http://www.ncbi.nlm.nih.gov/pubmed/24621972.
• Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: Definitions and distinctions for health-related research. Public Health Rep 1985; 100(2):126–31. http://www.ncbi.nlm.nih.gov/pubmed/3920711.
• Catapano AL, Graham I, Backer G de, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272. http://www.ncbi.nlm.nih.gov/pubmed/27567407.
• Chaitman BR, Alexander KP, Cyr DD, et al. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation 2021; 143(8):790–804. DOI: 10.1161/CIRCULATIONAHA.120.047987. http://www.ncbi.nlm.nih.gov/pubmed/33267610.
• Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352(3):238–44. http://www.ncbi.nlm.nih.gov/pubmed/15659723.
• Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography. Circulation 1997; 95(6):1686–744. http://www.ncbi.nlm.nih.gov/pubmed/9118558.
• Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003; 16(10):1091–110. http://www.ncbi.nlm.nih.gov/pubmed/14566308.
• Chen L, Wang X, Bao J, et al. Direct comparison of cardiovascular magnetic resonance and single-photon emission computed tomography for detection of coronary artery disease: A meta-analysis. PLoS. One. 2014; 9(2):e88402. DOI: 10.1371/journal.pone.0088402. http://www.ncbi.nlm.nih.gov/pubmed/24520382.
• Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: A meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53(11):936–46. DOI: 10.1016/j.jacc.2008.11.044. http://www.ncbi.nlm.nih.gov/pubmed/19281923.
• Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC. Cardiovasc Interv. 2012; 5(7):718–27. DOI: 10.1016/j.jcin.2012.03.022. http://www.ncbi.nlm.nih.gov/pubmed/22814776.
• Cholesterol Treatment Trialists' Ctt Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670–81. http://www.ncbi.nlm.nih.gov/pubmed/21067804.
• Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121(6):750–8. DOI: 10.1161/CIRCULATIONAHA.109.891523. http://www.ncbi.nlm.nih.gov/pubmed/20124123.
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38):2940–8. DOI: 10.1093/eurheartj/eht295. http://www.ncbi.nlm.nih.gov/pubmed/23907142.
• Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348:g1903. http://www.ncbi.nlm.nih.gov/pubmed/24690623.
• Chun AA, McGee SR. Bedside diagnosis of coronary artery disease: A systematic review. Am J Med 2004; 117(5):334–43. DOI: 10.1016/j.amjmed.2004.03.021. http://www.ncbi.nlm.nih.gov/pubmed/15336583.
• Cooper A, Calvert N, Skinner J, et al. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. London: National Clinical Guideline Centre for Acute and Chronic Conditions; 2010. http://www.nice.org.uk/nicemedia/live/12947/47931/47931.pdf.
• Cosmi B, Rubboli A, Castelvetri C, et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001(4):CD002133. DOI: 10.1002/14651858.CD002133. http://www.ncbi.nlm.nih.gov/pubmed/11687144.
• Costanzo S, Di Castelnuovo A, Donati MB, et al. Alcohol consumption and mortality in patients with cardiovascular disease: A meta-analysis. J Am Coll Cardiol 2010; 55(13):1339–47. DOI: 10.1016/j.jacc.2010.01.006. http://www.ncbi.nlm.nih.gov/pubmed/20338495.
• Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003; 290(1):86–97. DOI: 10.1001/jama.290.1.86. http://www.ncbi.nlm.nih.gov/pubmed/12837716.
• Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. Br Med J 1994; 309(6960):993–6. http://www.ncbi.nlm.nih.gov/pubmed/7950723.
• Dahal K, Hendrani A, Sharma SP, et al. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178(7):913-920. DOI: 10.1001/jamainternmed.2018.0850. http://www.ncbi.nlm.nih.gov/pubmed/29799995.
• Davidson KW, Bigger JT, Burg MM, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med 2013; 173(11):997–1004. DOI: 10.1001/jamainternmed.2013.915. http://www.ncbi.nlm.nih.gov/pubmed/23471421.
• Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: Coronary psychosocial evaluation studies randomized controlled trial. Arch. Intern. Med 2010; 170(7):600–8. DOI: 10.1001/archinternmed.2010.29. http://www.ncbi.nlm.nih.gov/pubmed/20386003.
• Deb S, Wijeysundera HC, Ko DT, et al. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: A systematic review. JAMA 2013; 310(19):2086–95. DOI: 10.1001/jama.2013.281718. http://www.ncbi.nlm.nih.gov/pubmed/24240936.
• Desai RR, Jha S. Diagnostic performance of cardiac stress perfusion MRI in the detection of coronary artery disease using fractional flow reserve as the reference standard: A meta-analysis. AJR Am J Roentgenol 2013; 201(2):W245-W252. DOI: 10.2214/AJR.12.10002. http://www.ncbi.nlm.nih.gov/pubmed/23883239.
• Desch S, Boudriot E, Rastan A, et al. Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials. Herz 2013; 38(1):48–56. DOI: 10.1007/s00059-012-3596-y. http://www.ncbi.nlm.nih.gov/pubmed/22407425.
• Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Haasenritter J, Bösner S, et al. Brustschmerz. DEGAM-Leitlinie Nr. 15. Düsseldorf: Omikron Publ; 2011. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/LL-15_Langfassung_Brustschmerz.pdf.
• Deutsche Gesellschaft für Kardiologie (DGK), Achenbach S, Hamm CW. ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Hebung (NSTE-ACS). Update 2011. 2012 [cited: 2015-06-09]. http://leitlinien.dgk.org/files/2012_Pocket-Leitlinie_Akutes_Koronarsyndrom_NSTE-ACS.pdf.
• Deutsche Gesellschaft für Kardiologie (DGK), Gohlke H, Gielen S, et al. ESC Pocketguideline Prävention von Herz-Kreislauferkrankungen. 2012 [cited: 2016-08-30]. http://leitlinien.dgk.org/files/PL_Pr%C3%A4vention_Internet_13.pdf.
• Deutsche Gesellschaft für Kardiologie (DGK), Zeymer, U., Kastrati A, Rassaf T, et al. ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit persistierender ST-Streckenhebung. Update 2012. 2012 [cited: 2015-06-09]. http://leitlinien.dgk.org/files/PL_STEMI_Internet_13.pdf.
• Deutsche Gesellschaft für Kardiologie (DGK). ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Streckenhebung (NSTE-ACS). Update 2015. Grünwald: Bruckmeier; 2016 (Pocket-Leitlinien). https://leitlinien.dgk.org/2016/pocket-leitlinie-akutes-koronarsyndrom-ohne-st-hebung-nste-acs-version-2015/.
• Deutsche Gesellschaft für Kardiologie (DGK). ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit ST-Streckenhebung (STEMI). Version 2017. Grünwald: Bruckmeier; 2018 (Pocket-Leitlinien). https://leitlinien.dgk.org/2018/pocket-leitlinie-therapie-des-akuten-herzinfarktes-bei-patienten-mit-st-streckenhebung-stemi-version-2017/.
• Deutsche Gesellschaft für Kardiologie (DGK). Infarkt-bedingter kardiogener Schock - Diagnose, Monitoring und Therapie. Langfassung. 2010 [cited: 2017-06-26]. http://www.awmf.org/uploads/tx_szleitlinien/019-013l_S3_Infarkt-bedingter_kardiogener_Schock_Diagnose_Monitoring_Therapie_2010-abgelaufen.pdf.
• Deutsche Gesellschaft für Nuklearmedizin (DGN), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Bengel F, et al. Myokard-Perfusions-Szintigraphie. 2012 [cited: 2015-01-06]. http://www.awmf.org/uploads/tx_szleitlinien/031-006l_S1_Myokard_Perfusions-Szintigraphie_2012-05_01.pdf.
• Deutsche Gesellschaft für Prävention und Rehabilitationvon Herz-Kreislauferkrankungen (DGPR), Bjarnason-Weherns B. Leitlinie körperliche Aktivität zur Sekundärprävention und Therapie kardiovaskulärer Erkrankungen. Clin Res Cardiol. Suppl 2009; 4(4 Suppl):1–44. DOI: 10.1007/s11789-009-0078-8.
• Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5. 2015 [cited: 2018-06-06]. DOI: 10.6101/AZQ/000364. http://doi.org/10.6101/AZQ/000364.
• Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006 (S3 Praxisleitlinien in Psychiatrie und Psychotherapie; 1).
• Deutsche Herzstiftung, editor. Deutscher Herzbericht 2020: 32. Sektorenübergreifende Versorgungsanalyse zur Kardiologie, Herzchirurgie und Kinderherzmedizin in Deutschland. Frankfurt: Deutsche Herzstiftung; 2021.
• Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. Stand: 18.10.2015. 2015 [cited: 2017-10-17]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf.
• Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychotherapeutische Medizin und ärztliche Psychotherapie (DGPM), Deutsches Kollegium für Psychosomatische Medizin (DKPM), et al. S3-Leitlinie. Posttraumatische Belastungsstörung. ICD 10: F 43.1. 2011 [cited: 2019-03-07]. https://www.awmf.org/uploads/tx_szleitlinien/051-010l_S3_Posttraumatische_Belastungsstoerung_2012-abgelaufen.pdf.
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381(9872):1107–15. DOI: 10.1016/S0140-6736(12)62177-1. http://www.ncbi.nlm.nih.gov/pubmed/23415013.
• Di Pasquale P, Alessi V, Barberi O, et al. The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: Safety and tolerability study. Int J Cardiol 2001; 77(2-3):119-27; discussion 128-9. http://www.ncbi.nlm.nih.gov/pubmed/11182173.
• Di Pasquale P, Cannizzaro S, Scalzo S, et al. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. Am Heart J 2005; 150(5):919. DOI: 10.1016/j.ahj.2005.03.032. http://www.ncbi.nlm.nih.gov/pubmed/16290961.
• Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease. J Am Coll Cardiol 1983; 1(2 Pt 1):444–55. http://www.ncbi.nlm.nih.gov/pubmed/6338081.
• Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328(7455):1519. http://www.ncbi.nlm.nih.gov/pubmed/15213107.
• Dunham RB. Nominal Group Technique: A Users' guide. Madison: Wisconsin School of Business; 1998.
• Dwight MM, Stoudemire A. Effects of depressive disorders on coronary artery disease: A review. Harv Rev Psychiatry 1997; 5(3):115–22. http://www.ncbi.nlm.nih.gov/pubmed/9385031.
• Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. Am Heart J 2013; 166(5):806–14. DOI: 10.1016/j.ahj.2013.07.031. http://www.ncbi.nlm.nih.gov/pubmed/24176435.
• Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. PLoS. One. 2012; 7(6):e38915. DOI: 10.1371/journal.pone.0038915. http://www.ncbi.nlm.nih.gov/pubmed/22745687.
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319–30. DOI: 10.1056/NEJMoa1709118. http://www.ncbi.nlm.nih.gov/pubmed/28844192.
• Elkayam U. Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114(8):667–77. http://www.ncbi.nlm.nih.gov/pubmed/2003715.
• Eller NH, Netterstrom B, Gyntelberg F, et al. Work-related psychosocial factors and the development of ischemic heart disease: A systematic review. Cardiol Rev 2009; 17(2):83–97. DOI: 10.1097/CRD.0b013e318198c8e9. http://www.ncbi.nlm.nih.gov/pubmed/19367150.
• Elwyn G, Edwards A, Mowle S, et al. Measuring the involvement of patients in shared decision-making: A systematic review of instruments. Patient Educ Couns. 2001; 43(1):5–22. http://www.ncbi.nlm.nih.gov/pubmed/11311834.
• Elwyn G, O'Connor AM, Bennett C, et al. Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi). PLoS. One. 2009; 4(3):e4705. DOI: 10.1371/journal.pone.0004705.
• Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018; 378(25):e34. DOI: 10.1056/NEJMoa1800389. http://www.ncbi.nlm.nih.gov/pubmed/29897866.
• Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.
• European Society of Cardiology. Cardiovascular Realities 2019. 2019 [cited: 2021-03-05]. https://www.flipsnack.com/Escardio/esc-cardiovascular-realities-2019/full-view.html.
• EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199–208. http://www.ncbi.nlm.nih.gov/pubmed/10109801.
• Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. J Psychiatr Res 2013; 47(11):1549–56. DOI: 10.1016/j.jpsychires.2013.07.011. http://www.ncbi.nlm.nih.gov/pubmed/23953755.
• Farkouh ME, Domanski M, Dangas GD, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol 2019; 73(6):629–38. DOI: 10.1016/j.jacc.2018.11.001. http://www.ncbi.nlm.nih.gov/pubmed/30428398.
• Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367(25):2375–84. DOI: 10.1056/NEJMoa1211585. http://www.ncbi.nlm.nih.gov/pubmed/23121323.
• Farooq V, van KD, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: Development and validation of SYNTAX score II. Lancet 2013; 381(9867):639–50. DOI: 10.1016/S0140-6736(13)60108-7. http://www.ncbi.nlm.nih.gov/pubmed/23439103.
• Fearon WF, Nishi T, Bruyne B de, et al. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation 2018; 137(5):480–7. DOI: 10.1161/CIRCULATIONAHA.117.031907. http://www.ncbi.nlm.nih.gov/pubmed/29097450.
• Fei Y, Guyatt GH, Alexander PE, et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval. Clin Pract. 2017; 24(1):222-231. DOI: 10.1111/jep.12663. http://www.ncbi.nlm.nih.gov/pubmed/28090731.
• Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014; 130(19):1749–67. DOI: 10.1161/CIR.0000000000000095. http://www.ncbi.nlm.nih.gov/pubmed/25070666.
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60(24):e44-e164. DOI: 10.1016/j.jacc.2012.07.013. http://www.ncbi.nlm.nih.gov/pubmed/23182125.
• Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: A scientific statement from the American Heart Association. Circulation 2013; 128(8):873–934. DOI: 10.1161/CIR.0b013e31829b5b44. http://www.ncbi.nlm.nih.gov/pubmed/23877260.
• Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2(10):1069–78. DOI: 10.1001/jamacardio.2017.2762. http://www.ncbi.nlm.nih.gov/pubmed/28832867.
• Fortuna D, Nicolini F, Guastaroba P, et al. Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: A comparative effectiveness study based on propensity score-matched cohorts. Eur J Cardiothorac Surg 2013; 44(1):e16-e24. DOI: 10.1093/ejcts/ezt197. http://www.ncbi.nlm.nih.gov/pubmed/23628951.
• Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371(12):1091–9. DOI: 10.1056/NEJMoa1406430. http://www.ncbi.nlm.nih.gov/pubmed/25176136.
• Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24):2503–15. http://www.ncbi.nlm.nih.gov/pubmed/19502645.
• Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385(9976):1397–405. DOI: 10.1016/S0140-6736(14)61368-4. http://www.ncbi.nlm.nih.gov/pubmed/25579834.
• Fung TT, Malik V, Rexrode KM, et al. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009; 89(4):1037–42. DOI: 10.3945/ajcn.2008.27140. http://www.ncbi.nlm.nih.gov/pubmed/19211821.
• Garcia MJ, Haines DE, Lai WW, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J Am Coll Cardiol 2011; 57(9):1126–66. DOI: 10.1016/j.jacc.2010.11.002. http://www.ncbi.nlm.nih.gov/pubmed/21349406.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht über Verordnungseinschränkungen und -ausschlüsse Alirocumab. 2016 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2676/2016-08-04_AM-RL-III_Alirocumab_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht über Verordnungseinschränkungen und -ausschlüsse Evolocumab. 2016 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2600/2016-06-02_AM-RL-III_Evolocumab_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III - Übersicht über Verordnungs-einschränkungen und –ausschlüsse Nummer 35a – Evolocumab. 2017 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2932/2017-04-20_AM-RL-III_Evolocumab_BAnz.pdf.
• Gencer B, Vaucher P, Herzig L, et al. Ruling out coronary heart disease in primary care patients with chest pain: A clinical prediction score. BMC Med 2010; 8:9. http://www.ncbi.nlm.nih.gov/pubmed/20092615.
• Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: Validation, updating, and extension. Eur Heart J 2011; 32(11):1316–30. DOI: 10.1093/eurheartj/ehr014. http://www.ncbi.nlm.nih.gov/pubmed/21367834.
• Gesundheitsberichterstattung des Bundes (GBE). Statistik der häufigsten Todesursachen 2003-2013. Abgerufen am 24.03.2015. 2015 [cited: 2015-03-30]. http://www.gbe-bund.de.
• Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80(1):87–98. http://www.ncbi.nlm.nih.gov/pubmed/2661056.
• Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40(8):1531–40. http://www.ncbi.nlm.nih.gov/pubmed/12392846.
• Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375(25):2423–34. DOI: 10.1056/NEJMoa1611594. http://www.ncbi.nlm.nih.gov/pubmed/27959713.
• Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017; 377(7):633–43. DOI: 10.1056/NEJMoa1701131. http://www.ncbi.nlm.nih.gov/pubmed/28813214.
• Gohlke H, Albus C, Bönner G, et al. CME Zertifizierte Fortbildung. Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Teil 4: Thrombozytenfunktionshemmer, Hormonersatztherapie, Verhaltensänderung und psychosoziale Risikofaktoren. Der Kardiologe 2013; 7(4):297–306. DOI: 10.1007/s12181-012-0469-9.
• Gorenoi V, Schonermark MP, Hagen A. CT coronary angiography vs. invasive coronary angiography in CHD. GMS Health Technol Assess 2012; 8:Doc02. DOI: 10.3205/hta000100. http://www.ncbi.nlm.nih.gov/pubmed/22536300.
• Gorenoi V, Schonermark MP, Hagen A. Perkutane Koronarinterventionen zusätzlich zur optimalen medikamentösen Therapie bei stabiler Angina Pectoris. 2011 (Schriftenreihe Health Technology Assessment; 115) [cited: 2018-11-22].
• Gosswald A, Schienkiewitz A, Nowossadeck E, et al. Prävalenz von Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):650–5. DOI: 10.1007/s00103-013-1666-9. http://www.ncbi.nlm.nih.gov/pubmed/23703482.
• Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. Ann Behav Med 2012; 43(3):299–310. DOI: 10.1007/s12160-011-9339-0. http://www.ncbi.nlm.nih.gov/pubmed/22237826.
• Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906):1115–22. http://www.ncbi.nlm.nih.gov/pubmed/7910229.
• Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389(10088):2473–81. DOI: 10.1016/S0140-6736(17)31075-9. http://www.ncbi.nlm.nih.gov/pubmed/28476288.
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.
• Haasenritter J, Bosner S, Vaucher P, et al. Ruling out coronary heart disease in primary care: External validation of a clinical prediction rule. Br J Gen Pract 2012; 62(599):e415-e421. DOI: 10.3399/bjgp12X649106. http://www.ncbi.nlm.nih.gov/pubmed/22687234.
• Habib PJ, Green J, Butterfield RC, et al. Association of cardiac events with coronary artery disease detected by 64-slice or greater coronary CT angiography: A systematic review and meta-analysis. Int J Cardiol 2013; 169(2):112–20. DOI: 10.1016/j.ijcard.2013.08.096. http://www.ncbi.nlm.nih.gov/pubmed/24090745.
• Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107(23):2900–7. http://www.ncbi.nlm.nih.gov/pubmed/12771008.
• Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: The HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38(29):2264–76. DOI: 10.1093/eurheartj/ehx162. http://www.ncbi.nlm.nih.gov/pubmed/28430910.
• Hakeem A, Garg N, Bhatti S, et al. Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta-analysis of Randomized Clinical Data. J Am Heart Assoc 2013; 2(4):e000354. DOI: 10.1161/JAHA.113.000354. http://www.ncbi.nlm.nih.gov/pubmed/23926119.
• Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on radiation dose and dose-optimization strategies in cardiovascular CT. J Cardiovasc Comput Tomogr 2011; 5(4):198–224. DOI: 10.1016/j.jcct.2011.06.001. http://www.ncbi.nlm.nih.gov/pubmed/21723512.
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(23):2999–3054. DOI: 10.1093/eurheartj/ehr236. http://www.ncbi.nlm.nih.gov/pubmed/21873419.
• Härter M, Loh A, Spies C. Gemeinsam entscheiden-erfolgreich behandeln. Neue Wege für Ärzte und Patienten im Gesundheitswesen. Köln: Dt. Ärzte-Verl.; 2005.
• Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107(20):2559–65. DOI: 10.1161/01.CIR.0000068340.96506.0F. http://www.ncbi.nlm.nih.gov/pubmed/12732605.
• He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. N Engl J Med 1999; 340(12):920–6. DOI: 10.1056/NEJM199903253401204. http://www.ncbi.nlm.nih.gov/pubmed/10089185.
• Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J 2014; 35(40):2821–30. DOI: 10.1093/eurheartj/ehu213. http://www.ncbi.nlm.nih.gov/pubmed/24849105.
• Head SJ, Kaul S, Mack MJ, et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 2013; 34(32):2510–8. DOI: 10.1093/eurheartj/eht059. http://www.ncbi.nlm.nih.gov/pubmed/23425523.
• Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: A pooled analysis of individual patient data. Lancet 2018; 391(10124):939–48. DOI: 10.1016/S0140-6736(18)30423-9. http://www.ncbi.nlm.nih.gov/pubmed/29478841.
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326):23–33. http://www.ncbi.nlm.nih.gov/pubmed/12114037.
• Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281(20):1927–36. http://www.ncbi.nlm.nih.gov/pubmed/10349897.
• Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4(10):829–39. DOI: 10.1016/S2213-8587(16)30156-5. http://www.ncbi.nlm.nih.gov/pubmed/27477773.
• Herrmann-Lingen C, Buss U. Angst und Depressivität im Verlauf der koronaren Herzkrankheit. Frankfurt/Main: VAS; 2002 (Statuskonferenz Psychokardiologie; 5). http://www.vasverlag.de/product_info.php?info=p231_Angst-und-Depressivitaet-im-Verlauf-der-koronaren-Herzkrankheit---Christoph-Herrmann-Lingen---Ullrich-Buss.html&XTCsid=0437b90aa1a4e4882078a99ccbb9939d.
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009; 119(23):3028–35. DOI: 10.1161/CIRCULATIONAHA.108.768986. http://www.ncbi.nlm.nih.gov/pubmed/19528344.
• Höfer S, Benzer W, Schüssler G, et al. Health-related quality of life in patients with coronary artery disease treated for angina: Validity and reliability of German translations of two specific questionnaires. Qual Life Res 2003; 12(2):199–212. http://www.ncbi.nlm.nih.gov/pubmed/12639066.
• Howlett JG, Stebbins A, Petrie MC, et al. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. JACC Heart Fail 2019; 7(10):878–87. DOI: 10.1016/j.jchf.2019.04.018. http://www.ncbi.nlm.nih.gov/pubmed/31521682.
• Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122(10):949–57. http://www.ncbi.nlm.nih.gov/pubmed/20733102.
• Huffman JC, Mastromauro CA, Beach SR, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: The Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med 2014; 174(6):927–35. DOI: 10.1001/jamainternmed.2014.739. http://www.ncbi.nlm.nih.gov/pubmed/24733277.
• Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347(13):969–74. http://www.ncbi.nlm.nih.gov/pubmed/12324552.
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2):119–77. DOI: 10.1093/eurheartj/ehx393. http://www.ncbi.nlm.nih.gov/pubmed/28886621.
• Iliou M-C, Pavy B, Martinez J, et al. Exercise training is safe after coronary stenting: A prospective multicentre study. Eur J Prev Cardiol 2015; 22(1):27–34. DOI: 10.1177/2047487313505819. http://www.ncbi.nlm.nih.gov/pubmed/24057686.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 5.0. Köln: IQWiG; 2017. http://www.iqwig.de/download/Allgemeine-Methoden_Version-5-0.pdf.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel plus Acetylsalicylsäure bei akutem Koronarsyndrom. Auftrag A04-01B. Version 1.0. 2009 (IQWiG-Berichte; 43) [cited: 2018-02-05]. http://www.iqwig.de/download/A04-01B_AB_Clopidogrel_plus_ASS_bei_akutem_Koronarsyndrom.pdf.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen. Abschlussbericht. Auftrag A04-01A. Version 1.0. 2006 [cited: 2019-02-20]. http://www.iqwig.de/download/A04-01A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Messung der myokardialen fraktionellen Flussreserve (FFR) bei koronarer Herzkrankheit. Abschlussbericht. Auftrag: D15-02. Version: 1.0. 2016 (IQWiG-Berichte; 462) [cited: 2020-04-02]. https://www.iqwig.de/download/D15-02_Abschlussbericht_Messung-der-fraktionellen-Flussreserve-bei-koronarer-Herzkrankheit.pdf.
• Irwig L, Glasziou P, Wilson A, et al. Estimating an individual's true cholesterol level and response to intervention. JAMA 1991; 266(12):1678–85. http://www.ncbi.nlm.nih.gov/pubmed/1886192.
• ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951):669–85. http://www.ncbi.nlm.nih.gov/pubmed/7661937.
• Iwata K, Nakagawa S, Ogasawara K. The prognostic value of normal stress cardiovascular magnetic resonance imaging. J Comput. Assist. Tomogr. 2014; 38(1):36–43. DOI: 10.1097/RCT.0b013e3182a474a0. http://www.ncbi.nlm.nih.gov/pubmed/24424555.
• Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N. Engl. J Med 2008; 358(17):1819–28. http://www.ncbi.nlm.nih.gov/pubmed/18375999.
• Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: A pooled analysis of 11 cohort studies. Am J Clin Nutr 2009; 89(5):1425–32. DOI: 10.3945/ajcn.2008.27124. http://www.ncbi.nlm.nih.gov/pubmed/19211817.
• Jong MC de, Genders TS, van Geuns RJ, et al. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: A systematic review and meta-analysis. Eur Radiol 2012; 22(9):1881–95. DOI: 10.1007/s00330-012-2434-1. http://www.ncbi.nlm.nih.gov/pubmed/22527375.
• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4):766–74. DOI: 10.1097/HJH.0b013e32835e2286. http://www.ncbi.nlm.nih.gov/pubmed/23337469.
• Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC. Cardiovasc Interv. 2008; 1(5):483–91. http://www.ncbi.nlm.nih.gov/pubmed/19463349.
• Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013; 43(5):1006–13. DOI: 10.1093/ejcts/ezt017. http://www.ncbi.nlm.nih.gov/pubmed/23413014.
• Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55(5):432–40. http://www.ncbi.nlm.nih.gov/pubmed/20117456.
• Katon WJ, Lin EH, Von KM, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010; 363(27):2611–20. DOI: 10.1056/NEJMoa1003955. http://www.ncbi.nlm.nih.gov/pubmed/21190455.
• Kazi DS, Penko J, Coxson PG, et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA 2017; 318(8):748–50. DOI: 10.1001/jama.2017.9924. http://www.ncbi.nlm.nih.gov/pubmed/28829863.
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371(9607):117–25. http://www.ncbi.nlm.nih.gov/pubmed/18191683.
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357(22):2248–61. DOI: 10.1056/NEJMoa0706201. http://www.ncbi.nlm.nih.gov/pubmed/17984166.
• Knuuti J, Bengel F, Bax JJ, et al. Risks and benefits of cardiac imaging: An analysis of risks related to imaging for coronary artery disease. Eur Heart J 2014; 35(10):633–8. DOI: 10.1093/eurheartj/eht512. http://www.ncbi.nlm.nih.gov/pubmed/24375074.
• Kopp IB, Selbmann HK, Koller M. Konsensufindung in evidenzbasierten Leitlinien - vom Mythos zur rationalen Strategie. Z Arztl. Fortbild. Qualitatssich. 2007; 101(2):89–95. DOI: 10.1016/j.zgesun.2007.01.002. http://www.ncbi.nlm.nih.gov/pubmed/17458353.
• Kotseva K, Wood D, Bacquer D de, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6):636–48. DOI: 10.1177/2047487315569401. http://www.ncbi.nlm.nih.gov/pubmed/25687109.
• Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc. Magn Reson. 2013; 15:91. DOI: 10.1186/1532-429X-15-91. http://www.ncbi.nlm.nih.gov/pubmed/24103764.
• Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch. Intern. Med 2007; 167(6):540–50. http://www.ncbi.nlm.nih.gov/pubmed/17389285.
• Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93(10):1826–35. http://www.ncbi.nlm.nih.gov/pubmed/8635262.
• Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am. J. Cardiol. 1999; 83(5):660–6. http://www.ncbi.nlm.nih.gov/pubmed/10080415.
• Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378(4):345–53. DOI: 10.1056/NEJMoa1702090. http://www.ncbi.nlm.nih.gov/pubmed/29365305.
• Ladwig KH, Lederbogen F, Albus C, et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie. Update 2013. Der Kardiologe 2013; 7(1):7–27. DOI: 10.1007/s12181-012-0478-8.
• Lancellotti P, Moura L, Pierard LA, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010; 11(4):307–32. DOI: 10.1093/ejechocard/jeq031. http://www.ncbi.nlm.nih.gov/pubmed/20435783.
• Landmesser U, Chapman MJ, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016; 38(29):2245–55. DOI: 10.1093/eurheartj/ehw480. http://www.ncbi.nlm.nih.gov/pubmed/27789571.
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14):1425–35. http://www.ncbi.nlm.nih.gov/pubmed/15755765.
• Laufs U. LDL-Senkung mit PCSK9-Hemmern: Was sagen die Leitlinien. Connexi 2017(6):54–7.
• Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 1997; 315(7114):973–80. http://www.ncbi.nlm.nih.gov/pubmed/9365294.
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326(7404):1423–7. http://www.ncbi.nlm.nih.gov/pubmed/12829554.
• Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344(24):1840–5. http://www.ncbi.nlm.nih.gov/pubmed/11407346.
• Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128(24):2567–76. DOI: 10.1161/CIRCULATIONAHA.113.002432. http://www.ncbi.nlm.nih.gov/pubmed/24056686.
• Li Q, Zhang Z, Yin RX. Drug-eluting stents or coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of four randomized trials and seventeen observational studies. Trials 2013; 14:133. DOI: 10.1186/1745-6215-14-133. http://www.ncbi.nlm.nih.gov/pubmed/23782856.
• Li S, Ni Q, Wu H, et al. Diagnostic accuracy of 320-slice computed tomography angiography for detection of coronary artery stenosis: Meta-analysis. Int J Cardiol 2013; 168(3):2699–705. DOI: 10.1016/j.ijcard.2013.03.023. http://www.ncbi.nlm.nih.gov/pubmed/23566493.
• Li X, Kong M, Jiang D, et al. Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: A meta-analysis. Interact Cardiovasc Thorac Surg 2014; 18(3):347–54. DOI: 10.1093/icvts/ivt509. http://www.ncbi.nlm.nih.gov/pubmed/24345688.
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89–118. http://www.ncbi.nlm.nih.gov/pubmed/15822172.
• Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: Systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129(12):1350–69. DOI: 10.1161/CIR.0000000000000019. http://www.ncbi.nlm.nih.gov/pubmed/24566200.
• Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J 2016; 37(6):536–45. DOI: 10.1093/eurheartj/ehv563. http://www.ncbi.nlm.nih.gov/pubmed/26578202.
• Liu Z, Hao H, Yin C, et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017; 8(25):41582–9. DOI: 10.18632/oncotarget.15078. http://www.ncbi.nlm.nih.gov/pubmed/28177908.
• Loh A, Simon D, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen - Effekte der Partizipativen Entscheidungsfindung aus systematischen Reviews. Dtsch Arztebl 2007; 104(21):A-1483-8.
• Ludt S, Angelow A, Baum E, et al. S3-Leitlinie Hausärztliche Risikoberatung zur kardiovaskulären Prävention: Registernummer 053-024, Version 2017-11_1. 2017 (DEGAM-Leitlinie; 19) [cited: 2018-06-11]. http://www.awmf.org/uploads/tx_szleitlinien/053-024l_Hausaerztliche_Risikoberat_kardiovask_Praevention_2017-11_1.pdf.
• Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis. Am J Clin Nutr 2014; 100(1):256–69. DOI: 10.3945/ajcn.113.076109. http://www.ncbi.nlm.nih.gov/pubmed/24847854.
• Luo L, Yuan X, Huang W, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: A meta-analysis. Intern Med J 2015; 45(5):546–57. DOI: 10.1111/imj.12706. http://www.ncbi.nlm.nih.gov/pubmed/25644680.
• Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): A prospective, randomised, open-label, non-inferiority trial. Lancet 2016; 388(10061):2743–52. DOI: 10.1016/S0140-6736(16)32052-9. http://www.ncbi.nlm.nih.gov/pubmed/27810312.
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28):2159–219. DOI: 10.1093/eurheartj/eht151. http://www.ncbi.nlm.nih.gov/pubmed/23771844.
• Mant J, McManus RJ, Oakes RA, et al. Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care. Health Technol Assess 2004; 8(2):iii1-iii158. http://www.ncbi.nlm.nih.gov/pubmed/14754562.
• Mark DB, Schulman KA. PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA 2017; 318(8):711–2. DOI: 10.1001/jama.2017.8907. http://www.ncbi.nlm.nih.gov/pubmed/28829851.
• Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020; 382(15):1395–407. DOI: 10.1056/NEJMoa1915922. http://www.ncbi.nlm.nih.gov/pubmed/32227755.
• Martin LR, M DR, editors. The Oxford handbook of health communication, behavior change, and treatment adherence. New York: Oxford Univ. Pr; 2014.
• McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch. Intern. Med 1998; 158(11):1238–44. http://www.ncbi.nlm.nih.gov/pubmed/9625403.
• McGillion M, O'Keefe-McCarthy S, Carroll SL, et al. Impact of self-management interventions on stable angina symptoms and health-related quality of life: A meta-analysis. BMC Cardiovasc Disord 2014; 14:14. DOI: 10.1186/1471-2261-14-14. http://www.ncbi.nlm.nih.gov/pubmed/24483947.
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14(8):803–69. DOI: 10.1093/eurjhf/hfs105. http://www.ncbi.nlm.nih.gov/pubmed/22828712.
• McRobbie H, Bullen C, Glover M, et al. New Zealand smoking cessation guidelines. N Z Med J 2008; 121(1276):57–70. http://www.ncbi.nlm.nih.gov/pubmed/18574510.
• Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009; 53(19):1760–8. DOI: 10.1016/j.jacc.2009.01.035. http://www.ncbi.nlm.nih.gov/pubmed/19422982.
• Mensink GB, Schienkiewitz A, Haftenberger M, et al. Übergewicht und Adipositas in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):786–94. DOI: 10.1007/s00103-012-1656-3. http://www.ncbi.nlm.nih.gov/pubmed/23703499.
• Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: A meta-analysis. J Am Coll Cardiol 2007; 49(2):227–37. DOI: 10.1016/j.jacc.2006.08.048. http://www.ncbi.nlm.nih.gov/pubmed/17222734.
• Minneboo M, Lachman S, Snaterse M, et al. Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial. J Am Coll Cardiol 2017; 70(3):318–27. DOI: 10.1016/j.jacc.2017.05.041. http://www.ncbi.nlm.nih.gov/pubmed/28705312.
• Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001; 141(1):41–6. DOI: 10.1067/mhj.2001.111258. http://www.ncbi.nlm.nih.gov/pubmed/11136485.
• Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381(9867):629–38. DOI: 10.1016/S0140-6736(13)60141-5. http://www.ncbi.nlm.nih.gov/pubmed/23439102.
• Montalescot G, Collet JP, Ecollan P, et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study. J Am Coll Cardiol 2014; 64(24):2563–71. DOI: 10.1016/j.jacc.2014.08.053. http://www.ncbi.nlm.nih.gov/pubmed/25524333.
• Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38):2949–3003. DOI: 10.1093/eurheartj/eht296. http://www.ncbi.nlm.nih.gov/pubmed/23996286.
• Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. 2nd ed. Göttingen: Hogrefe; 2011.
• Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial. Eur Heart J 2016; 37(48):3588–95. DOI: 10.1093/eurheartj/ehw388. http://www.ncbi.nlm.nih.gov/pubmed/27572070.
• Morice MC, Serruys PW, Kappetein AP, et al. Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the SYNTAX Trial. Circulation 2014; 129(23):2388–94. DOI: 10.1161/CIRCULATIONAHA.113.006689. http://www.ncbi.nlm.nih.gov/pubmed/24700706.
• Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 2009; 63(2 Suppl):S22-S33. DOI: 10.1038/sj.ejcn.1602976. http://www.ncbi.nlm.nih.gov/pubmed/19424216.
• Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med 2006; 354(15):1601–13. DOI: 10.1056/NEJMra054035. http://www.ncbi.nlm.nih.gov/pubmed/16611951.
• Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: A systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010; 7(3):e1000252. http://www.ncbi.nlm.nih.gov/pubmed/20351774.
• MSD Sharp und Dohme. Die Behandlung mit Tredaptive (Nicotinsäure/Laropiprant, MSD) muss beendet werden. 2013 (Rote-Hand-Briefe) [cited: 2018-05-15]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/20130121.pdf.
• Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101(6):590–3. http://www.ncbi.nlm.nih.gov/pubmed/10673248.
• Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Nature 1998; 2(3):i-88. http://www.ncbi.nlm.nih.gov/pubmed/9561895.
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. Am J Med 2012; 125(9):882–7. DOI: 10.1016/j.amjmed.2011.12.013. http://www.ncbi.nlm.nih.gov/pubmed/22748400.
• Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009; 10(2):165–93. DOI: 10.1093/ejechocard/jep007. http://www.ncbi.nlm.nih.gov/pubmed/19270053.
• Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: A meta-analysis. J Am Coll Cardiol 2007; 50(14):1343–53. http://www.ncbi.nlm.nih.gov/pubmed/17903634.
• National Institute for Health and Care Excellence (NICE), Adams P, Benett I, et al. MI: Secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. Partial update of NICE CG 48.Methods, evidence and recommendations. 2013 (NICE Clinical Guideline; 48) [cited: 2016-04-21]. http://www.nice.org.uk/guidance/cg172/evidence/myocardial-infarction-secondary-prevention-full-guideline-248682925.
• National Institute for Health and Care Excellence (NICE), Wierzbicki A, Ahmad R, et al. Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.Nice clinical guideline CG 181. 2014 (NICE Clinical Guideline; 181) [cited: 2016-04-21]. http://www.nice.org.uk/guidance/cg181/evidence/lipid-modification-update-full-guideline-243786637.
• National Institute for Health and Care Excellence (NICE). Appendix A: Summary of new evidence from 4-year surveillance of Myocardial infarction. 2016 (NICE Guideline; 172) [cited: 2018-06-13]. http://www.nice.org.uk/guidance/cg172/evidence/appendix-a-summary-of-new-evidence-pdf-4479686174.
• National Institute for Health and Care Excellence (NICE). Management of stable angina. Last modified: December 2012. London: NICE; 2011 (NICE Clinical Guideline; 126). http://www.nice.org.uk/guidance/cg126/resources/guidance-management-of-stable-angina-pdf.
• National Institute for Health and Care Excellence (NICE). Stable angina; 2011 (NICE Clinical Guideline; 126). http://www.nice.org.uk/guidance/cg126/evidence/full-guideline-pdf-183176605.
• Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163(1):40–51. DOI: 10.7326/M14-2957. http://www.ncbi.nlm.nih.gov/pubmed/25915661.
• New York University School of Medicine (NYU). International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA). 2015 [cited: 2019-03-18]. https://clinicaltrials.gov/ct2/show/record/NCT01471522.
• Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: A meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27(23):2763–74. DOI: 10.1093/eurheartj/ehl338. http://www.ncbi.nlm.nih.gov/pubmed/17082208.
• Nielsen LH, Ortner N, Norgaard BL, et al. The diagnostic accuracy and outcomes after coronary computed tomography angiography vs. conventional functional testing in patients with stable angina pectoris: A systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014; 15(9):961–71. DOI: 10.1093/ehjci/jeu027. http://www.ncbi.nlm.nih.gov/pubmed/24618659.
• Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport 2010; 13(5):496–502. DOI: 10.1016/j.jsams.2009.09.008. http://www.ncbi.nlm.nih.gov/pubmed/20005170.
• Nussbaumer B, Glechner A, Kaminski-Hartenthaler A, et al. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int 2016; 113(26):445–53. DOI: 10.3238/arztebl.2016.0445. http://www.ncbi.nlm.nih.gov/pubmed/27412989.
• O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(4):e362-e425. DOI: 10.1161/CIR.0b013e3182742cf6. http://www.ncbi.nlm.nih.gov/pubmed/23247304.
• Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am. J. Cardiol. 1991; 67(13):1084–9. http://www.ncbi.nlm.nih.gov/pubmed/2024598.
• Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: A meta-analysis. Obesity (Silver. Spring) 2008; 16(2):442–50. DOI: 10.1038/oby.2007.36. http://www.ncbi.nlm.nih.gov/pubmed/18239657.
• Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA 2000; 284(23):3008–14. http://www.ncbi.nlm.nih.gov/pubmed/11122587.
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5):487–97. DOI: 10.1056/NEJMra050100. http://www.ncbi.nlm.nih.gov/pubmed/16079372.
• Pack QR, Rodriguez-Escudero JP, Thomas RJ, et al. The prognostic importance of weight loss in coronary artery disease: A systematic review and meta-analysis. Mayo Clin Proc 2014; 89(10):1368–77. DOI: 10.1016/j.mayocp.2014.04.033. http://www.ncbi.nlm.nih.gov/pubmed/25199859.
• Park DW, Kim YH, Yun SC, et al. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol 2010; 56(17):1366–75. http://www.ncbi.nlm.nih.gov/pubmed/20946993.
• Park S-J, Ahn J-M, Kim Y-H, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372(13):1204–12. DOI: 10.1056/NEJMoa1415447. http://www.ncbi.nlm.nih.gov/pubmed/25774645.
• Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364(18):1718–27. http://www.ncbi.nlm.nih.gov/pubmed/21463149.
• Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. Circ Cardiovasc Imaging 2012; 5(6):700–7. DOI: 10.1161/CIRCIMAGING.112.978270. http://www.ncbi.nlm.nih.gov/pubmed/23051888.
• Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28(20):2539–50. DOI: 10.1093/eurheartj/ehm037. http://www.ncbi.nlm.nih.gov/pubmed/17428822.
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med 2000; 160(4):459–67. http://www.ncbi.nlm.nih.gov/pubmed/10695686.
• Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20(9):1021–41. DOI: 10.1016/j.echo.2007.07.003. http://www.ncbi.nlm.nih.gov/pubmed/17765820.
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290(21):2805–16. http://www.ncbi.nlm.nih.gov/pubmed/14657064.
• Perk J, Backer G de, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33(13):1635–701. DOI: 10.1093/eurheartj/ehs092. http://www.ncbi.nlm.nih.gov/pubmed/22555213.
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29):2315–81. DOI: 10.1093/eurheartj/ehw106. http://www.ncbi.nlm.nih.gov/pubmed/27222591.
• Ponikowski P, Anker S, Voors AA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed with the special contribution Heart Failure Association (HFA) of the ESC. 2016 [cited: 2019-10-01]. http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure.
• Powell H, Cosson P. Comparison of 64-slice computed tomography angiography and coronary angiography for the detection and assessment of coronary artery disease in patients with angina: A systematic review. Radiogr 2013; 19(2):168–75. DOI: 10.1016/j.radi.2012.12.005.
• Powell R, McGregor G, Ennis S, et al. Is exercise-based cardiac rehabilitation effective? A systematic review and meta-analysis to re-examine the evidence. BMJ Open 2018; 8(3):e019656. DOI: 10.1136/bmjopen-2017-019656. http://www.ncbi.nlm.nih.gov/pubmed/29540415.
• Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56(9):702–6. http://www.ncbi.nlm.nih.gov/pubmed/12177089.
• Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: A systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012; 5(4):476–90. DOI: 10.1161/CIRCINTERVENTIONS.112.970954. http://www.ncbi.nlm.nih.gov/pubmed/22872053.
• Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525–31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.
• Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016; 23(18):1914–39. DOI: 10.1177/2047487316671181. http://www.ncbi.nlm.nih.gov/pubmed/27777324.
• Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2):194–202. http://www.ncbi.nlm.nih.gov/pubmed/12517230.
• Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2017; 4:CD002902. DOI: 10.1002/14651858.CD002902.pub4. http://www.ncbi.nlm.nih.gov/pubmed/28452408.
• Richardson S, Shaffer JA, Falzon L, et al. Meta-analysis of perceived stress and its association with incident coronary heart disease. Am. J. Cardiol. 2012; 110(12):1711–6. DOI: 10.1016/j.amjcard.2012.08.004. http://www.ncbi.nlm.nih.gov/pubmed/22975465.
• Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: Potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016; 37(17):1373–9. DOI: 10.1093/eurheartj/ehw046. http://www.ncbi.nlm.nih.gov/pubmed/26916794.
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16):1489–99. DOI: 10.1056/NEJMoa1501031. http://www.ncbi.nlm.nih.gov/pubmed/25773378.
• Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A meta-analysis. Psychosom Med 2010; 72(6):563–9. DOI: 10.1097/PSY.0b013e3181dbff97. http://www.ncbi.nlm.nih.gov/pubmed/20410247.
• Roest AM, Martens EJ, Jonge P de, et al. Anxiety and risk of incident coronary heart disease: A meta-analysis. J Am Coll Cardiol 2010; 56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034. http://www.ncbi.nlm.nih.gov/pubmed/20620715.
• Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3):267–315. DOI: 10.1093/eurheartj/ehv320. http://www.ncbi.nlm.nih.gov/pubmed/26320110.
• Rollman BL, Belnap BH, LeMenager MS, et al. The Bypassing the Blues treatment protocol: Stepped collaborative care for treating post-CABG depression. Psychosom Med 2009; 71(2):217–30. DOI: 10.1097/PSY.0b013e3181970c1c. http://www.ncbi.nlm.nih.gov/pubmed/19188529.
• Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet 2006; 368(9536):666–78. DOI: 10.1016/S0140-6736(06)69251-9. http://www.ncbi.nlm.nih.gov/pubmed/16920472.
• Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ 2011; 342:d671. http://www.ncbi.nlm.nih.gov/pubmed/21343207.
• Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation 2016; 134(24):e653-e699. DOI: 10.1161/CIR.0000000000000461. http://www.ncbi.nlm.nih.gov/pubmed/27881567.
• Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials. Lancet 2018; 392(10145):387–99. DOI: 10.1016/S0140-6736(18)31133-4. http://www.ncbi.nlm.nih.gov/pubmed/30017552.
• Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: A systematic review and meta-analysis. Br J Gen Pract 2005; 55(513):305–12. http://www.ncbi.nlm.nih.gov/pubmed/15826439.
• Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23(7):685–713. DOI: 10.1016/j.echo.2010.05.010. http://www.ncbi.nlm.nih.gov/pubmed/20620859.
• Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013; 75(4):335–49. DOI: 10.1097/PSY.0b013e318291d798. http://www.ncbi.nlm.nih.gov/pubmed/23630306.
• Sa MP, Soares AM, Lustosa PC, et al. Meta-analysis of 5674 patients treated with percutaneous coronary intervention and drug-eluting stents or coronary artery bypass graft surgery for unprotected left main coronary artery stenosis. Eur J Cardiothorac Surg 2013; 43(1):73–80. DOI: 10.1093/ejcts/ezs204. http://www.ncbi.nlm.nih.gov/pubmed/22518037.
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18):1713–22. DOI: 10.1056/NEJMoa1615664. http://www.ncbi.nlm.nih.gov/pubmed/28304224.
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001–9. http://www.ncbi.nlm.nih.gov/pubmed/8801446.
• Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3–10. http://www.ncbi.nlm.nih.gov/pubmed/11136953.
• Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78(7):1684–92. http://www.ncbi.nlm.nih.gov/pubmed/24759796.
• Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev 2017; 2:CD011747. DOI: 10.1002/14651858.CD011747.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28178363.
• Sänger S, Lang B, Klemperer D, et al. Manual Patienteninformation. Empfehlungen zur Erstellung evidenzbasierter Patienteninformationen. Berlin: ÄZQ; 2006 (äzq Schriftenreihe; 25). http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe25.pdf.
• Sarno G, Decraemer I, Vanhoenacker PK, et al. On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: A comparison with invasive angiography. JACC. Cardiovasc Interv. 2009; 2(6):550–7. DOI: 10.1016/j.jcin.2009.03.009. http://www.ncbi.nlm.nih.gov/pubmed/19539260.
• Scherer M, Wagner H.O., Lühmann D, et al. Multimorbidität. S3-Leitlinie. AWMF-Register-Nr. 053-047. 2017 (DEGAM-Leitlinie; 20) [cited: 2018-06-06]. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-047_Multimorbiditaet/053-047l_%20Multimorbiditaet_redakt_24-1-18.pdf.
• Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017; 4:CD011748. DOI: 10.1002/14651858.CD011748.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28453187.
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379(22):2097-2107. DOI: 10.1056/NEJMoa1801174. http://www.ncbi.nlm.nih.gov/pubmed/30403574.
• Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. A national clinical guideline. Updated February 2013. Edinburgh: SIGN; 2013 (SIGN Publications; 93). http://www.sign.ac.uk/pdf/sign93.pdf.
• Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. Edinburgh: SIGN; 2016 (SIGN Publications; 148). http://www.sign.ac.uk/sign-148-acute-coronary-syndrome.html.
• Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360(10):961–72. http://www.ncbi.nlm.nih.gov/pubmed/19228612.
• Servier Deutschland GmbH, Gelbe Liste Online. Procoralan® 5 mg, Filmtbl. Fachinformation. 2018 [cited: 2018-06-08]. http://www.gelbe-liste.de/produkte/Procoralan-5-mg-Filmtbl_481159/fachinformation.
• Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2008; 9(4):415–37. DOI: 10.1093/ejechocard/jen175. http://www.ncbi.nlm.nih.gov/pubmed/18579481.
• Siegrist J, Broer M, Junge A. PLC. Profil der Lebensqualität chronisch Kranker. Göttingen: Hogrefe; 1995.
• Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316(12):1289–97. DOI: 10.1001/jama.2016.13985. http://www.ncbi.nlm.nih.gov/pubmed/27673306.
• Sipahi I, Akay MH, Dagdelen S, et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: Meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014; 174(2):223–30. DOI: 10.1001/jamainternmed.2013.12844. http://www.ncbi.nlm.nih.gov/pubmed/24296767.
• Sixt S, Beer S, Bluher M, et al. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J 2010; 31(1):112–9. DOI: 10.1093/eurheartj/ehp398. http://www.ncbi.nlm.nih.gov/pubmed/19793768.
• Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart 2010; 96(12):974–8. DOI: 10.1136/hrt.2009.190066. http://www.ncbi.nlm.nih.gov/pubmed/20538674.
• Smith SC, Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol 2014; 64(6):601–12. DOI: 10.1016/j.jacc.2014.06.1159. http://www.ncbi.nlm.nih.gov/pubmed/25104531.
• Snow V, Barry P, Fihn SD, et al. Evaluation of primary care patients with chronic stable angina: Guidelines from the American College of Physicians. Ann Intern Med 2004; 141(1):57–64. http://www.ncbi.nlm.nih.gov/pubmed/15238371.
• Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92(5):1189–96. DOI: 10.3945/ajcn.2010.29673. http://www.ncbi.nlm.nih.gov/pubmed/20810976.
• Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25(2):333–41. http://www.ncbi.nlm.nih.gov/pubmed/7829785.
• Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4(4):CD001431. DOI: 10.1002/14651858.CD001431.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28402085.
• Ständige Impfkommission am Robert Koch Institut (STIKO). Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut - 2017/2018. Epidemiol Bull RKI 2017(34):333–80. DOI: 10.17886/EpiBull-2017-044.
• Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20):2569–619. DOI: 10.1093/eurheartj/ehs215. http://www.ncbi.nlm.nih.gov/pubmed/22922416.
• Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials. JAMA Intern Med 2014; 174(2):232–40. DOI: 10.1001/jamainternmed.2013.12855. http://www.ncbi.nlm.nih.gov/pubmed/24296791.
• Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: Meta-analysis of randomized controlled trials. Arch. Intern. Med 2012; 172(4):312–9. DOI: 10.1001/archinternmed.2011.1484. http://www.ncbi.nlm.nih.gov/pubmed/22371919.
• Stone GW, Kappetein AP, Sabik JF, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med 2019; 381(19):1820–30. DOI: 10.1056/NEJMoa1909406. http://www.ncbi.nlm.nih.gov/pubmed/31562798.
• Stone GW, Sabik JF, Serruys PW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 2016; 375(23):2223–35. DOI: 10.1056/NEJMoa1610227. http://www.ncbi.nlm.nih.gov/pubmed/27797291.
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2):S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a. http://www.ncbi.nlm.nih.gov/pubmed/24222016.
• Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA 2010; 303(12):1159–66. DOI: 10.1001/jama.2010.297. http://www.ncbi.nlm.nih.gov/pubmed/20332401.
• Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008; 51(9):885–92. DOI: 10.1016/j.jacc.2007.09.067. http://www.ncbi.nlm.nih.gov/pubmed/18308155.
• Takagi H, Yamamoto H, Iwata K, et al. Drug-eluting stents increase late mortality compared with coronary artery bypass grafting in triple-vessel disease: A meta-analysis of randomized controlled and risk-adjusted observational studies. Int J Cardiol 2012; 159(3):230–3. DOI: 10.1016/j.ijcard.2012.05.046. http://www.ncbi.nlm.nih.gov/pubmed/22664367.
• Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77(4):917–25. http://www.ncbi.nlm.nih.gov/pubmed/23502990.
• Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104(5):539–43. http://www.ncbi.nlm.nih.gov/pubmed/11479250.
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645):1231–9. DOI: 10.1016/S0140-6736(08)61240-4. http://www.ncbi.nlm.nih.gov/pubmed/18757089.
• Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation 1989; 79(6):1171–9. http://www.ncbi.nlm.nih.gov/pubmed/2785870.
• Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014(4):CD003331. DOI: 10.1002/14651858.CD003331.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24771460.
• The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Postgrad. Med 2005; Spec No:1–111. http://www.ncbi.nlm.nih.gov/pubmed/17203560.
• Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009; 53(25):2324–31. DOI: 10.1016/j.jacc.2009.03.032. http://www.ncbi.nlm.nih.gov/pubmed/19539141.
• Thomas S, Gokhale R, Boden WE, et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013; 29(4):472–82. DOI: 10.1016/j.cjca.2012.07.010. http://www.ncbi.nlm.nih.gov/pubmed/23010084.
• Thomopoulos C, Skalis G, Michalopoulou H, et al. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clin Cardiol 2015; 38(12):763–9. DOI: 10.1002/clc.22441. http://www.ncbi.nlm.nih.gov/pubmed/26282344.
• Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345(8953):811–6. http://www.ncbi.nlm.nih.gov/pubmed/7898227.
• Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: Systematic review and meta-analysis. BMJ 2013; 347:f6879. http://www.ncbi.nlm.nih.gov/pubmed/24355537.
• Thuijs DJ, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019; 394(10206):1325–34. DOI: 10.1016/S0140-6736(19)31997-X. http://www.ncbi.nlm.nih.gov/pubmed/31488373.
• Tonne C, Schwartz J, Mittleman M, et al. Long-term survival after acute myocardial infarction is lower in more deprived neighborhoods. Circulation 2005; 111(23):3063–70. DOI: 10.1161/CIRCULATIONAHA.104.496174. http://www.ncbi.nlm.nih.gov/pubmed/15939820.
• Trappe HJ, Lollgen H. Leitlinien zur Ergometrie. Z Kardiol 2000; 89(9):821–31. http://www.ncbi.nlm.nih.gov/pubmed/11077695.
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59(24):2159–64. DOI: 10.1016/j.jacc.2012.02.026. http://www.ncbi.nlm.nih.gov/pubmed/22520250.
• U.S. Department of Health and Human Services, Fiore MC, Jaén CR, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. 2008 [cited: 2017-04-20]. http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/treating_tobacco_use08.pdf.
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015; 373(21):2038–47. DOI: 10.1056/NEJMoa1503943. http://www.ncbi.nlm.nih.gov/pubmed/26466021.
• Uzunhasan I, Yildiz A, Coskun U, et al. Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction. Scand J Clin Lab Invest 2009; 69(5):545–9. DOI: 10.1080/00365510902802278. http://www.ncbi.nlm.nih.gov/pubmed/19347740.
• Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65(8):805–15. DOI: 10.1016/j.jacc.2014.11.053. http://www.ncbi.nlm.nih.gov/pubmed/25720624.
• van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol 2017; 232:294–303. DOI: 10.1016/j.ijcard.2016.12.125. http://www.ncbi.nlm.nih.gov/pubmed/28094128.
• Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016; 374(16):1511–20. DOI: 10.1056/NEJMoa1602001. http://www.ncbi.nlm.nih.gov/pubmed/27040723.
• Verdon F, Herzig L, Burnand B, et al. Chest pain in daily practice: Occurrence, causes and management. Swiss Med Wkly 2008; 138(23-24):340–7. http://www.ncbi.nlm.nih.gov/pubmed/18561039.
• Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg 2015; 15:112. DOI: 10.1186/s12893-015-0096-z. http://www.ncbi.nlm.nih.gov/pubmed/26467661.
• Virtanen M, Ferrie JE, Singh-Manoux A, et al. Overtime work and incident coronary heart disease: The Whitehall II prospective cohort study. Eur Heart J 2010; 31(14):1737–44. DOI: 10.1093/eurheartj/ehq124. http://www.ncbi.nlm.nih.gov/pubmed/20460389.
• Visser CA, Kan G, David GK, et al. Echocardiographic-cineangiographic correlation in detecting left ventricular aneurysm: A prospective study of 422 patients. Am. J. Cardiol. 1982; 50(2):337–41. http://www.ncbi.nlm.nih.gov/pubmed/7102561.
• Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008; 14(2):140–4. DOI: 10.1016/j.cardfail.2007.10.013. http://www.ncbi.nlm.nih.gov/pubmed/18325461.
• Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. JAMA Psychiatry 2015; 72(4):334–41. DOI: 10.1001/jamapsychiatry.2014.2502. http://www.ncbi.nlm.nih.gov/pubmed/25671328.
• Wang R, Serruys PW, Gao C, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J 2021; 43(1):56–67. DOI: 10.1093/eurheartj/ehab441. http://www.ncbi.nlm.nih.gov/pubmed/34405232.
• Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: Systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 2014; 349:g4490. http://www.ncbi.nlm.nih.gov/pubmed/25073782.
• Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473–83. http://www.ncbi.nlm.nih.gov/pubmed/1593914.
• Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220–33. http://www.ncbi.nlm.nih.gov/pubmed/8628042.
• Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366(16):1467–76. DOI: 10.1056/NEJMoa1110717. http://www.ncbi.nlm.nih.gov/pubmed/22452338.
• Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018; 39(26):2484–93. DOI: 10.1093/eurheartj/ehy220. http://www.ncbi.nlm.nih.gov/pubmed/29722796.
• Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134(21):e468-e495. DOI: 10.1161/CIR.0000000000000456. http://www.ncbi.nlm.nih.gov/pubmed/27754879.
• Wijeysundera HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: Effects of percutaneous coronary intervention versus medical therapy on angina relief. Ann Intern Med 2010; 152(6):370–9. DOI: 10.7326/0003-4819-152-6-201003160-00007. http://www.ncbi.nlm.nih.gov/pubmed/20231568.
• Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31(20):2501–55. http://www.ncbi.nlm.nih.gov/pubmed/20802248.
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2):145–54. DOI: 10.1056/NEJMoa1212914. http://www.ncbi.nlm.nih.gov/pubmed/23796131.
• Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111(25):3366–73. DOI: 10.1161/CIRCULATIONAHA.104.502815. http://www.ncbi.nlm.nih.gov/pubmed/15967851.
• Won H, Her AY, Kim BK, et al. Percutaneous Coronary Intervention Is More Beneficial Than Optimal Medical Therapy in Elderly Patients with Angina Pectoris. Yonsei Med J 2016; 57(2):382–7. DOI: 10.3349/ymj.2016.57.2.382. http://www.ncbi.nlm.nih.gov/pubmed/26847290.
• World Health Organization (WHO). Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee. WHO Tech Rep Ser 1993; 831:1–122. http://www.ncbi.nlm.nih.gov/pubmed/8351937.
• Wormser D, Kaptoge S, Di AE, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet 2011; 377(9771):1085–95. http://www.ncbi.nlm.nih.gov/pubmed/21397319.
• Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009(3):CD001841. http://www.ncbi.nlm.nih.gov/pubmed/19588327.
• Wu C-T, Wang Z-H, Li Z-Q, et al. Effect of spironolactone on cardiac remodeling after acute myocardial infarction. World J Emerg Med 2013; 4(1):48–53. DOI: 10.5847/wjem.j.1920-8642.2013.01.009. http://www.ncbi.nlm.nih.gov/pubmed/25215092.
• Xaplanteris P, Fournier S, Pijls NH, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med 2018; 379(3):250–9. DOI: 10.1056/NEJMoa1803538. http://www.ncbi.nlm.nih.gov/pubmed/29785878.
• Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344(8922):563–70. http://www.ncbi.nlm.nih.gov/pubmed/7914958.
• Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am. J. Cardiol. 2002; 89(2A):18A-25A. http://www.ncbi.nlm.nih.gov/pubmed/11835907.
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13:123. DOI: 10.1186/s12916-015-0358-8. http://www.ncbi.nlm.nih.gov/pubmed/26099511.
• Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: An updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012; 15(4):725–37. DOI: 10.1017/S1368980011002254. http://www.ncbi.nlm.nih.gov/pubmed/21914258.
• Zhou T, Yang LF, Zhai JL, et al. SPECT myocardial perfusion versus fractional flow reserve for evaluation of functional ischemia: A meta analysis. Eur J Radiol 2014; 83(6):951–6. DOI: 10.1016/j.ejrad.2014.02.018. http://www.ncbi.nlm.nih.gov/pubmed/24666512.
• Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: Meta-analysis of individual patient data. Eur Heart J 2019; 40(2):180–6. DOI: 10.1093/eurheartj/ehy812. http://www.ncbi.nlm.nih.gov/pubmed/30596995.

Inhalt

• 1 Definition (2019)
• 2 Epidemiologie (2016)
  • 2.1 Ischämische Herzkrankheiten in der Todesursachenstatistik
  • 2.2 Lebenszeitprävalenz ischämischer Herzkrankheiten
• 3 Schweregrade und Klassifizierungen (2016)
• 4 Diagnostik bei (Verdacht auf) KHK (2016)
  • 4.1 Diagnose einer stenosierenden KHK als Ursache von Beschwerden oder Verdacht auf Progression
  • 4.2 Psychosoziale Diagnostik
  • 4.3 Diagnostische Verfahren zur Therapieplanung
  • 4.4 Routinemäßige Verlaufsbeobachtung von Patienten mit gesicherter stenosierender KHK
• 5 Therapieplanung und gemeinsame Entscheidungsfindung (2019)
  • 5.1 Evidenzbasierte Patientenmaterialien
  • 5.2 Individuelle Therapieziele
  • 5.3 Selbstmanagement
  • 5.4 Multimorbidität
• 6 Konservative, nicht-medikamentöse Therapie (2019)
  • 6.1 Gesprächsführung, Motivation, Steigerung der Adhärenz
  • 6.2 Training und Bewegung
  • 6.3 Ernährung
  • 6.4 Gewichtsmanagement
  • 6.5 Alkoholkonsum
  • 6.6 Tabakkonsum
  • 6.7 Psychosoziale Risikofaktoren und psychische Komorbidität
• 7 Medikamentöse Therapie (2019)
  • 7.1 Thrombozytenaggregationshemmer
  • 7.2 Lipidsenker
  • 7.3 Betarezeptorenblocker
  • 7.4 Hemmer des RAA-Systems
  • 7.5 Symptomatische Therapie und Prophylaxe der Angina pectoris
  • 7.6 Weitere Maßnahmen
• 8 Revaskularisationstherapie (2022)
  • 8.1 Einführung und Hintergrund
  • 8.2 Messung der fraktionellen Flussreserve (FFR) als Unterstützung bei Revaskularisationsverfahren
  • 8.3 Allgemeine Empfehlungen: Entscheidung über die Revaskularisation
  • 8.4 Wahl des Revaskularisationsverfahrens
• 9 Rehabilitation (2019)
  • 9.1 Phase I: Frühmobilisation
  • 9.2 Phase II: Anschlussheilbehandlung und Anschlussrehabilitation
  • 9.3 Phase III: Langzeitbehandlung
• 10 Versorgungskoordination und Langzeitbetreuung (2019)
• Methodik
  • I Einführung
  • II Zielsetzung, Adressaten, Anwendungsbereich
  • III Quellen, Evidenz und Empfehlungsgrade
  • IV Formales Konsensusverfahren
  • V Umgang mit Interessenkonflikten
• Impressum
  • Herausgeber
  • Gültigkeitsdauer und Fortschreibung
  • Fassungen der Leitlinie
  • Autoren der Version 6.0
  • Methodische Begleitung und Koordination
• Tabellenverzeichnis
• Abbildungsverzeichnis
• Abkürzungsverzeichnis
• Glossar
• Entscheidungshilfen / Patientenblätter
  • Patientenblatt: Welche Untersuchungen kommen für mich in Frage?
  • Patientenblatt: Entscheidungen gemeinsam besprechen
  • Patientenblatt: Warum Ernährung und Bewegung wichtig sind
  • Patientenblatt: Warum es hilft, aufs Rauchen zu verzichten
  • Entscheidungshilfe: Verdacht auf koronare Herzkrankheit: Brauche ich eine Herzkatheter-Untersuchung?
  • Entscheidungshilfe: Katheter-Untersuchung bei koronarer Herzkrankheit: Stents einsetzen oder erstmal abwarten?
  • Entscheidungshilfe: Verengte Herzkranzgefäße: Stent oder Bypass?
  • Patientenblatt: Warum empfiehlt mir meine Ärztin oder mein Arzt Statine?
• Literaturliste